Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

被引：5
|
作者：
Perkins, Andrew Charles
Burbury, Kate
Lehmann, Thomas
Ross, David M.
Reiter, Andreas
Gupta, Vikas
Harrison, Claire
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Wondergem, Marielle
Pack, Robert
Wroclawska, Monika
Wilke, Celine
Zhang, Angela
Heidel, Florian H.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140408
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)
    Robert, Caroline
    Dummer, Reinhard
    Arance, Ana
    Ribas, Antoni
    Weber, Jeffrey
    Long, Georgina V.
    Haanen, John
    Nathan, Paul
    Ascierto, Paolo A.
    Gasal, Eduard
    D'Amelio, Anthony
    Bettinger, Severine
    Boran, Aislyn D.
    Schadendorf, Dirk
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    International Journal of Hematology, 2017, 105 : 309 - 317
  • [3] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Komatsu, Norio
    Kirito, Keita
    Shimoda, Kazuya
    Ishikawa, Takayuki
    Ohishi, Kohshi
    Ohyashiki, Kazuma
    Takahashi, Naoto
    Okada, Hikaru
    Amagasaki, Taro
    Yonezu, Toshio
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 309 - 317
  • [4] Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
    Norio Komatsu
    Keita Kirito
    Kazuya Shimoda
    Takayuki Ishikawa
    Kohshi Ohishi
    Kazuma Ohyashiki
    Naoto Takahashi
    Hikaru Okada
    Taro Amagasaki
    Toshio Yonezu
    Koichi Akashi
    International Journal of Hematology, 2017, 105 : 387 - 387
  • [5] A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
    Weber, J.
    Long, G. V.
    Haanen, J. B.
    Arance, A.
    Dummer, R.
    Nathan, P.
    Ribas, A.
    Ascierto, P. A.
    Robert, C.
    Gasal, E.
    D'Amelio, A., Jr.
    Bettinger, S.
    Boran, A. D.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Moshe Talpaz
    Susan Erickson-Viitanen
    Kevin Hou
    Solomon Hamburg
    Maria R. Baer
    Journal of Hematology & Oncology, 11
  • [7] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Talpaz, Moshe
    Erickson-Viitanen, Susan
    Hou, Kevin
    Hamburg, Solomon
    Baer, Maria R.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [8] A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
    Dilley, Kimberley
    Harb, Jason
    Jalaluddin, Muhammad
    Hutti, Jessica E.
    Potluri, Jalaja
    BLOOD, 2020, 136
  • [9] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhou, Hu
    Duan, Minghui
    Gao, Sujun
    He, Guangsheng
    Jing, Hongmei
    Li, Junmin
    Ma, Liangming
    Zhu, Huanling
    Chang, Chunkang
    Du, Xin
    Hong, Mei
    Li, Xin
    Liu, Qingchi
    Wang, Wei
    Xu, Na
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Xiao, Zhijian
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, : 1588 - 1597
  • [10] A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis
    Oritani, Kenji
    Okamoto, Shinichiro
    Tauchi, Tetsuzo
    Saito, Shigeki
    Ohishi, Kohshi
    Handa, Hiroshi
    Takenaka, Katsuto
    Gopalakrishna, Prashanth
    Amagasaki, Taro
    Ito, Kazuo
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (03) : 295 - 304
12345